Epidermal growth factor receptor T790M detection using liquid biopsy was evaluated in a real-life setting in 120 advanced non–small-cell lung cancer patients whose disease had progressed during first- or second-generation tyrosine kinase inhibitors. The T790M detection rate was 25.8% using liquid biopsy and 49.2% after tissue rebiopsy. Liquid biopsies performed before disease progression according to Response Evaluation Criteria In Solid Tumors were all negative for T790M and T790M positivity was higher in cases of extrathoracic metastatic sites.

Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study / Minari, R.; Mazzaschi, G.; Bordi, P.; Gnetti, L.; Alberti, G.; Altimari, A.; Gruppioni, E.; Sperandi, F.; Parisi, C.; Guaitoli, G.; Bettelli, S.; Longo, L.; Bertolini, F.; Pagano, M.; Bonelli, C.; Tagliavini, E.; Nicoli, D.; Ubiali, A.; Zangrandi, A.; Trubini, S.; Proietto, M.; Fiorentino, M.; Tiseo, M.. - In: CLINICAL LUNG CANCER. - ISSN 1525-7304. - 21:5(2020), pp. e464-e473. [10.1016/j.cllc.2020.02.021]

Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study

Minari R.;Mazzaschi G.;Bordi P.;Tiseo M.
2020-01-01

Abstract

Epidermal growth factor receptor T790M detection using liquid biopsy was evaluated in a real-life setting in 120 advanced non–small-cell lung cancer patients whose disease had progressed during first- or second-generation tyrosine kinase inhibitors. The T790M detection rate was 25.8% using liquid biopsy and 49.2% after tissue rebiopsy. Liquid biopsies performed before disease progression according to Response Evaluation Criteria In Solid Tumors were all negative for T790M and T790M positivity was higher in cases of extrathoracic metastatic sites.
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study / Minari, R.; Mazzaschi, G.; Bordi, P.; Gnetti, L.; Alberti, G.; Altimari, A.; Gruppioni, E.; Sperandi, F.; Parisi, C.; Guaitoli, G.; Bettelli, S.; Longo, L.; Bertolini, F.; Pagano, M.; Bonelli, C.; Tagliavini, E.; Nicoli, D.; Ubiali, A.; Zangrandi, A.; Trubini, S.; Proietto, M.; Fiorentino, M.; Tiseo, M.. - In: CLINICAL LUNG CANCER. - ISSN 1525-7304. - 21:5(2020), pp. e464-e473. [10.1016/j.cllc.2020.02.021]
File in questo prodotto:
File Dimensione Formato  
Minari et al manuscript_Clean_Edited_Clean.pdf

Open Access dal 02/03/2021

Descrizione: Articolo principale
Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 384.39 kB
Formato Adobe PDF
384.39 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2881511
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact